" Its a long term stock without news it can drift lower and u keep adding."
If you really thing the long-term outlook is good, a better idea might be to wait 'till it stops falling and starts advancing and then start adding. It's almost certain it will drift back to the $2.50 range in the next 3 to 6 months. Waiting for that entry point would reduce your losses if AGEN continues to deliver nothing, as it has done for 15 years now.
The pattern is slightly changed. It now looks like it may take 2 days to eliminate the morning's exuberance. Who would have thunk AGEN could hold 25% of a gain for a whole day! as Bob Dylan once wrote:- "The times they are a changing.", and just when Garo had swapped his options for hard, cold cash salary.
".if someone wanted to plunge into immunotherapy and wanted a fairly mature pipeline"
Since that has not happened, I guess nobody wants to be a Dendreon!
You obviously have not heard the tale of the The Scorpion and the Frog. Despite the total lack of logic both here, and with that sad tale, there's only one possible outcome.
Don't be fooled into thinking Agenus is now a different animal. The frog could not escape the scorpion's nature and Agenus shareholders cannot escape the market's doubts.
This is how it is. Don't drive yourself crazy thinking it's different this time. You'll just wind up floating belly up, with the frog.
I was like you 10 years ago but I've changed. If AGEN announced they had a pill that, taken annually, allowed people to live healthy lives to the age of 250, the pps would jump 50% and then drop 70%.
For whatever reason the market puts no credibility on cancer vaccines. Perhaps Dendreon has put a curse on this industry segment!
There are no weak or strong hands - only smart and stupid. We don't know who is show yet. The market will make that known in time.
When you get to the site, just click on the 'PutAVirusOnMyPC' link on the main page. The title on the link is "Easily make 20k a week" so you'll never even know about the virus. How simple is that?
There are drug candidates just emerging from pre-clinical trials now which will likely be on the market before final Reduce-It data is available. That's the unfortunate reality here. The market is therefore valuing post Reducit-It Vascepa value at nothing, which is normal given the time frame involved. If you want to wait, you need to forget about your AMRN shares for a few years and pray Amarin does not dilute you to insignificance during the wait. That's the bet here and it's not a bet most people would take.
What I'm saying is this:- If everything Thero tries fails, then why not reverse course and do the opposite. It can't get any worse for shareholders. We're headed for total destruction. Perhaps by crashing at full speed, some shareholders will be thrown free of the wreckage!
do a 1 for 20 reverse now than it would be to wait for the Nasdaq to force the issue. There's no bottom in sight and we're nearly out of run-way. Amarin, with its currently approved high Vascepa trigs indication is now worth about half what an inferior drug fetched in this same indication PRE-approval. We have reached extreme level s where the laws of physics no longer apply. In a similar situation, the crew of star trek increased speed to pass through impending doom. Hey, don't knock it, it worked for Gene Roddenberry.
I wish voting your post down could influence its accuracy. Unfortunately it cannot. Amarin is between a rock and a hard place. It reminds me of a mistake I made early in my investing life. I used margin to purchase stock that was fundamentally undervalued. Well, the market pushed the stock even further down before it regained its normal value at 5 times my purchase price. If I didn't have access to non-broker finance, I'd have lost the stock at the bottom at half my purchase price. I don't think Amarin will be as lucky with Reduce-It. If the chances of RI succeeding were viewed as good by the experts in the space, large pharma, Amarin would have no problem partnering its way out of its current situation. Given that has not happened and we all know we're not as smart as large pharma, it's way past time to make serious decisions here. Had we accepted this truth earlier, we'd all likely have dumped in the teens.
Seems peculiar, especially when one considers the much stronger balance sheet of Syneron and the products of both companies.